(Q35093616)

6 August 2017

1 reference

title

VEGF blocking therapy in the treatment of cancer (English)

1 reference

6 August 2017

Julia Glade-Bender

1

1 reference

6 August 2017

Jessica J Kandel

series ordinal

2

1 reference

6 August 2017

Darrell J Yamashiro

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

Expert Opinion on Biological Therapy

6 August 2017

1 reference

6 August 2017

3

1 reference

6 August 2017

2

1 reference

6 August 2017

263-276

1 reference

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

6 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Molecular biology of the VEGF and the VEGF receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Angiozyme: a novel angiogenesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

KDR receptor: a key marker defining hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Expression of vascular permeability factor in glioblastoma specimens: correlation with tumor vascular endothelial surface and peritumoral edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Effect of p53 status on tumor response to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

VASCULAR ENDOTHELIAL GROWTH FACTOR AS PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

Serum Soluble Vascular Cell Adhesion Molecule-1: Role as a Surrogate Marker of Angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.263

21 January 2018

Identifiers

DOI

10.1517/14712598.3.2.263

1 reference

6 August 2017

1 reference